Tourmaline Bio (TRML) Competitors $23.40 +0.37 (+1.61%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$23.50 +0.10 (+0.43%) As of 08/29/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRML vs. CNTA, DNLI, AGIO, IDYA, IBRX, HRMY, RXRX, OCUL, IRON, and CGONShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), ImmunityBio (IBRX), Harmony Biosciences (HRMY), Recursion Pharmaceuticals (RXRX), Ocular Therapeutix (OCUL), Disc Medicine (IRON), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. Its Competitors Centessa Pharmaceuticals Denali Therapeutics Agios Pharmaceuticals IDEAYA Biosciences ImmunityBio Harmony Biosciences Recursion Pharmaceuticals Ocular Therapeutix Disc Medicine CG Oncology Centessa Pharmaceuticals (NASDAQ:CNTA) and Tourmaline Bio (NASDAQ:TRML) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Is CNTA or TRML more profitable? Tourmaline Bio's return on equity of -30.50% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.39% -29.87% Tourmaline Bio N/A -30.50%-29.63% Do insiders and institutionals hold more shares of CNTA or TRML? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer CNTA or TRML? Centessa Pharmaceuticals currently has a consensus price target of $31.50, suggesting a potential upside of 87.61%. Tourmaline Bio has a consensus price target of $50.14, suggesting a potential upside of 114.29%. Given Tourmaline Bio's higher probable upside, analysts clearly believe Tourmaline Bio is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CNTA or TRML? In the previous week, Centessa Pharmaceuticals had 6 more articles in the media than Tourmaline Bio. MarketBeat recorded 11 mentions for Centessa Pharmaceuticals and 5 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.35 beat Centessa Pharmaceuticals' score of 1.27 indicating that Tourmaline Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tourmaline Bio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, CNTA or TRML? Tourmaline Bio has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M328.23-$235.76M-$1.79-9.38Tourmaline BioN/AN/A-$73.21M-$3.43-6.82 Which has more risk and volatility, CNTA or TRML? Centessa Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. SummaryTourmaline Bio beats Centessa Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$601.20M$2.51B$5.71B$9.76BDividend YieldN/A48.51%6.66%4.48%P/E Ratio-6.8222.6183.1026.57Price / SalesN/A731.65544.91112.35Price / CashN/A26.3325.6628.92Price / Book2.005.3711.766.08Net Income-$73.21M$32.95M$3.27B$265.84M7 Day Performance3.17%-0.65%1.13%0.36%1 Month Performance7.54%6.46%8.30%5.58%1 Year Performance38.87%-3.15%62.26%19.67% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio2.5248 of 5 stars$23.40+1.6%$50.14+114.3%+38.9%$601.20MN/A-6.8244News CoveragePositive NewsCNTACentessa Pharmaceuticals2.5736 of 5 stars$17.00-0.1%$28.10+65.3%+24.4%$2.28B$6.85M-9.50200News CoveragePositive NewsAnalyst ForecastDNLIDenali Therapeutics4.2498 of 5 stars$15.57+0.5%$33.62+115.9%-37.5%$2.26B$330.53M-5.56430News CoveragePositive NewsAGIOAgios Pharmaceuticals4.42 of 5 stars$37.26-4.0%$56.33+51.2%-17.9%$2.25B$36.50M3.39390News CoveragePositive NewsIDYAIDEAYA Biosciences4.4795 of 5 stars$24.71-1.6%$48.09+94.6%-37.8%$2.20B$7M-6.5280Positive NewsIBRXImmunityBio2.1489 of 5 stars$2.25-2.6%$10.75+377.8%-40.8%$2.18B$14.74M-4.69590HRMYHarmony Biosciences4.5005 of 5 stars$37.42-1.2%$51.00+36.3%+2.5%$2.18B$772.53M12.07200Positive NewsRXRXRecursion Pharmaceuticals1.9176 of 5 stars$4.83-2.2%$7.00+44.9%-35.4%$2.14B$58.84M-2.71400Positive NewsOCULOcular Therapeutix3.9459 of 5 stars$11.87-3.5%$17.20+44.9%+38.4%$2.14B$63.72M-9.27230Positive NewsIRONDisc Medicine3.5924 of 5 stars$59.41-1.6%$98.30+65.5%+17.4%$2.10BN/A-13.2930News CoveragePositive NewsCGONCG Oncology1.454 of 5 stars$25.42-5.6%$55.27+117.4%-27.3%$2.05B$1.14M-14.3661 Related Companies and Tools Related Companies Centessa Pharmaceuticals Alternatives Denali Therapeutics Alternatives Agios Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives ImmunityBio Alternatives Harmony Biosciences Alternatives Recursion Pharmaceuticals Alternatives Ocular Therapeutix Alternatives Disc Medicine Alternatives CG Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRML) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRML Stock Alerts